

Sustaining The HIV Prevention Research Agenda

Funding for Research and Development of HIV Vaccines, Microbicides and other New Prevention Options 2000-2007

HIV Vaccines and Microbicides Resource Tracking Working Group

**AIDS Vaccine Advocacy Coalition, Secretariat
Alliance for Microbicide Development
International AIDS Vaccine Initiative
Joint United Nations Programme on HIV/AIDS**

The HIV Vaccines & Microbicides Resource Tracking Working Group



Research is four things: brains with which to think, eyes with which to see, machines with which to measure and, fourth, **money**.


Albert Szent-Györgyi
1937 Nobel Laureate in Medicine

Global R&D investment has **significantly** increased since 2000 for each of these new prevention options :


- HIV Vaccines
- Microbicides
- Adult Male Circumcision
- Cervical Barriers
- Herpes Suppression
- Pre-exposure prophylaxis using antiretroviral drugs (PrEP).

Global Investment in HIV Prevention R&D in 2007

US\$ Millions




Key HIV Prevention Research Funders in 2007



HIV Vaccine R&D Funding 2000-2007

	2000	2001	2002	2003	2004	2005	2006	2007
<i>Public sector</i>								
- US	272	314	376	463	516	574	654	659
- Europe	23	32	39	44	57	69	82	79
- Other	12	14	23	26	30	29	40	51
<i>Total public</i>	307	359	436	532	602	672	776	789
<i>Philanthropic</i>								
	20	7	112	15	12	12	78	88
Total non-commercial								
	327	366	548	547	614	684	854	877
<i>Commercial</i>								
					68	75	79	84
Total global investment								
	327	355	548	547	682	759	933	961



Annual Investments in HIV Vaccine R&D 2000-2007



*Data on Pharmaceutical and Biotechnology investments collected only after 2003

Vaccine Expenditures*

2000-2007




*Based upon a subset of total expenditures for which allocations could be calculated.

Microbicide R&D Funding 2000-2007

	2000	2001	2002	2003	2004	2005	2006	2007
<i>Public sector</i>								
- US	34.6	61.3	75.3	78.8	92	101.6	129.7	139.8
- Europe	0.7	0.4	5.1	10.6	29.9	30.3	56.3	59.6
- Other	0.3	0.3	0.6	0.9	2.2	10.7	6.1	3.6
Total public	35.7	62.0	81.0	90.2	124.2	142.6	191.2	203.0
<i>Philanthropic</i>	29.4	3.4	24.8	16.9	18.1	21.3	26.2	19.0
Total non-commercial	65.1	65.4	105.8	107.1	142.3	163.9	217.4	222.0
<i>Commercial</i>					4.5	4.5	4.5	4.5
Total global investment	65.1	65.4	105.8	107.1	146.8	168.4	221.9	226.5

Annual Investments in Microbicide R&D by Sector



2000-2007



*Data on Pharmaceutical and Biotechnology investments collected only after 2003


Microbicide Expenditures*

2006-2007




*Based upon a subset of total expenditures for which allocations could be calculated.


Annual Investment in Adult Male Circumcision R&D by Sector (US\$ mil)




Annual Investment in Herpes Suppression R&D by Sector (US\$ mil)



Annual Investment in Cervical Barriers R&D by Sector (US\$ mil)




Annual Investment in PrEP by Sector (US\$ mil)




Annual Investments in Pre-Exposure Prophylaxis


2002-2007




2002




2003




2004



2005



2006



2007

Legend


 Public Sector

 Philanthropic Sector


 Commercial Sector

A comprehensive, integrated & sustained response

An expanded alphabet soup of prevention:
ABC (male & female), clean needles, *male circumcision*, VCT



International AIDS Assistance: Trends in G8/EC & Other Donor Government Assistance, 2002-2007




Source: Kaiser Foundation and UNAIDS; HVMRTWG

Where we've been...


- For more than a decade, we advocates have been optimistic that with more resources, more cooperation and more scientific knowledge, new preventive technologies could be found in time to stem the growing epidemic...

Research that Could Re-define Prevention, 9/06



Source: www.avac.org

Research That Is Re-defining Prevention, 8/08



Source: www.avac.org

Where we must go...

- Sustain momentum in HIV prevention R&D investment;
- Increasing transparency and more accountability by linking research and funding to scientific priorities;
- Integrate vaccines, microbicides and other new prevention options into the comprehensive response to the epidemic; and
- Develop and validate estimates of R&D investment need for all new prevention options

The Working Group would like to thank the many individuals from the public, philanthropic, and commercial sectors who provided us with information and whose participation was essential to the completion of this project.

Support for this project was provided by the AIDS Vaccine Advocacy Coalition (AVAC), the Alliance for Microbicide Development (AMD), the International AIDS Vaccine Initiative (IAVI), the International Partnership for Microbicides (IPM) and the Joint United Nations Programme on HIV/AIDS (UNAIDS).

For a copy of this year's report visit www.hivresourcetracking.org.

